Wells Fargo raised the firm’s price target on Arcturus Therapeutics to $58 from $45 and keeps an Overweight rating on the shares. The firm has increased confidence in the size of potential Japan government order for Kostaive.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARCT:
- ARCT Earnings this Week: How Will it Perform?
- Options Volatility and Implied Earnings Moves This Week, March 04 – March 07, 2024
- EC grants ‘orphan medicinal product designation’ to Arcturus’ ARCT-032 for CF
- ARCT: Why Have Analysts Rated this Small-Cap Biotech Stock a “Strong Buy”?
- Arcturus Therapeutics price target raised to $48 from $40 at Citi
